

316 Horsley Road Milperra NSW 2214

8 September 2009

Australian Securities Exchange Limited Company Announcements Office

20 Bridge Street Sydney NSW 2000

### Jasham Integration

Healthzone Limited [ASX: HZL], the wellness and beauty sector producer, distributor and retailer, has today announced the issue of 2,039,349 new fully paid ordinary shares to the vendors of the Jasham in accordance with the business acquisition agreement completed in June 2008 (refer ASX release 30 June 2008). The Appendix 3B follows. Half the shares are held under voluntary escrow and are then available for trading after 31 January 2010 with the remaining 50% escrowed to 31 July 2010.

Peter Roach, Chairman of Healthzone Limited said: "Jasham has proven to be a good acquisition for Healthzone with its actual contribution consistent with that estimated at acquisition. Further we are focused on expanding company branded products distribution into the Jasham pharmacy channel of over 1,700 pharmacies in addition to Jasham's traditional fragrance and beauty products".

Peter Roach. MAICD Healthzone Limited Chairman Tel (02) 9772 7100

#### **About Healthzone**

Healthzone (ASX: HZL) operates a portfolio of integrated consumer product, distribution and retail businesses in the wellness and beauty sectors. Each business provides immediate opportunities for earnings growth through business development and integration.

The company is a leading distributor of health foods, skincare and beauty products and operates Australia's largest health food franchise. Its Health Minders business is the leading health food distributor to the Australian health food channel, and owner of Australia's leading national health franchise Healthy Life with more than 120 stores. Healthzone owns and operates nine Healthzone retail stores and the Healthzone store master franchise, and produces the Aurinda range of supplement and vitamin products and Bod range of skincare and beauty products. The company was listed on the Australian Securities Exchange in 2006 and its website is www.healthzone.com.au.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ 1/7/96. \ Origin: Appendix \ 5. \ Amended \ 1/7/98, \ 1/9/99, \ 1/7/2000, \ 30/9/2001, \ 11/3/2002, \ 1/1/2003, \ 24/10/2005.$ 

g information.
ch sheets if there is not enough space).
Ordinary shares
2,039,349
Fully paid ordinary shares

Name of entity

HEALTHZONE LIMITED

24/10/2005 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not

• the date from which they do

rank equally, please state:

- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

The securities rank equally in all respects with existing ordinary shares

5 Issue price or consideration

Total consideration \$600,000

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Deferred consideration for the acquisition of the Jasham business

- 7 Dates of entering \*securities into uncertificated holdings or despatch of certificates
- 8 September 2009
- 8 Number and \*class of all \*securities quoted on ASX (*including* the securities in clause 2 if applicable)

Number	+Class
49,089,299	Ordinary shares

Appendix 3B Page 2 24/10/2005

<sup>+</sup> See chapter 19 for defined terms.

		Number	<sup>+</sup> Class
9	Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)	None	
	D: : 1		
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)		
Part	2 - Bonus issue or pro r	rata issue	
11	Is security holder approval required?	NA	
12	Is the issue renounceable or non-renounceable?	NA	
13	Ratio in which the *securities will be offered	NA	
	<sup>+</sup> Class of <sup>+</sup> securities to which the	NIA	
14	offer relates	NA	
15	<sup>+</sup> Record date to determine entitlements	NA	
_	XA7:11 1 1 1: 1: CC	T N T A	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?		
	Policy for deciding entitlements	NA	
17	in relation to fractions	INA	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	NA	
	Note: Security holders must be told how their entitlements are to be dealt with.		
	Cross reference: rule 7.7.		
19	Closing date for receipt of	NA	
19	acceptances or renunciations	11/1	

1/1/2003 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B New issue announcement

20	Names of any underwriters	NA
	numes of unity under writers	
21	Amount of any underwriting fee	NA
	or commission	
22	Names of any brokers to the	NA
	issue	
23	Fee or commission payable to the broker to the issue	NA
	the broker to the issue	
24	Amount of any handling fee	NA
	payable to brokers who lodge acceptances or renunciations on	
	behalf of *security holders	
25	If the issue is contingent on	NA
25	*security holders' approval, the	INA
	date of the meeting	
26	Date entitlement and acceptance	NA
	form and prospectus or Product	
	Disclosure Statement will be sent to persons entitled	
	1	
27	If the entity has issued options, and the terms entitle option	NA
	holders to participate on	
	exercise, the date on which notices will be sent to option	
	holders	
0	D	D.Y.A.
28	Date rights trading will begin (if applicable)	NA
29	Date rights trading will end (if applicable)	NA
	иррпсионе	
30	How do *security holders sell	NA
	their entitlements in full through	
	a broker?	
31	How do *security holders sell	NA
	part of their entitlements through a broker and accept for	
	the balance?	

Appendix 3B Page 4 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

32	How do *security holders dispose of their entitlements	NA
	(except by sale through a	
	broker)?	
33	<sup>+</sup> Despatch date	NA
Part	3 - Quotation of securities	es
You ne	ed only complete this section if you are o	applying for quotation of securities
34	Type of securities	
	(tick one)	
(a)	Securities described in Part	1
(b)	All other securities	
	•	end of the escrowed period, partly paid securities that become fully paid, nen restriction ends, securities issued on expiry or conversion of convertible
Entiti	es that have ticked box 34(a)	
Addi	tional securities forming a nev	w class of securities
T' 1 ,	. 1	
i ick to locum	indicate you are providing the informa ents	tion or
35		ty securities, the names of the 20 largest holders of , and the number and percentage of additional olders
36	If the *securities are *equit	y securities, a distribution schedule of the additional
<i>)</i> •	+securities setting out the r	number of holders in the categories
	1 - 1,000 1,001 - 5,000	
	5,001 - 10,000 10,001 - 100,000	
	100,001 and over	
37	A copy of any trust deed for	r the additional <sup>+</sup> securities

1/1/2003 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

# Entities that have ticked box 34(b)

38	Number of securities for which <sup>+</sup> quotation is sought	NA	
39	Class of *securities for which quotation is sought	NA	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest	NA	
	<ul> <li>payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another security, clearly identify that other security)	NA	
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number NA	+Class

Appendix 3B Page 6 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Director)	Date: 8 September 2009
Print name:	Peter Roach	
	== == == ==	

24/10/2005 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.